Biopharmaceuticals

At Celonic, our vision is to become a fully-integrated biopharmaceutical company. Following this strategy, Celonic owns a comprehensive pipeline of proprietary therapeutic proteins. That comprises drugs in the fields of cancer and immune diseases e.g. rheumatoid arthritis or Crohn’s disease. For all therapeutic proteins, proof-of-concept was successfully shown in an animal model in at least one indication. Celonic is planning to partly out-license these APIs after a certain step of development for defined indications. In other indications, Celonic aims to place them on the market autonomously.